Globeflex Capital’s Biogen BIIB Stock Holding History

Globeflex Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-24	Closed	-$6K	–	455
2020 Q4	$6K	Hold	24	–	–	﹤0.01%	438
2020 Q3	$7K	Hold	24	–	–	﹤0.01%	430
2020 Q2	$6K	Hold	24	–	–	﹤0.01%	456
2020 Q1	$8K	Hold	24	–	–	﹤0.01%	450
2019 Q4	$7K	Hold	24	–	–	﹤0.01%	451
2019 Q3	$6K	Hold	24	–	–	﹤0.01%	439
2019 Q2	$6K	Buy	+24	New	+$5.54K	﹤0.01%	432
2014 Q3	–	Sell	-12	Closed	-$3K	–	569
2014 Q2	$3K	Sell	12 -1	-8%	-$301	﹤0.01%	417
2014 Q1	$3K	Hold	13	–	–	﹤0.01%	398
2013 Q4	$3K	Buy	13 +1	+8%	+$259	﹤0.01%	397
2013 Q3	$2K	Hold	12	–	–	﹤0.01%	423
2013 Q2	$2K	Buy	+12	New	+$2.56K	﹤0.01%	418

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Globeflex Capital's BIIB Position: Q1 2021 in Review

Globeflex Capital sold out of Biogen (BIIB) in Q1 2021, closing a stake of 24 shares — an estimated $6K sold.

Globeflex Capital first reported a position in BIIB in Q2 2013 and held it in 12 quarters. The position peaked at $8K in Q1 2020. 1,094 funds tracked by Wall St. Rank hold BIIB as of Q1 2021.

Globeflex Capital reported no remaining Biogen position as of Q1 2021 after selling out during the quarter.
Globeflex Capital sold 24 Biogen shares in Q1 2021, an estimated $6K.
Globeflex Capital first reported a position in Biogen in Q2 2013 and held it in 12 quarters.
Globeflex Capital's Biogen position peaked at $8K in Q1 2020.
1,094 funds tracked by Wall St. Rank held Biogen as of Q1 2021.

Based on Globeflex Capital's 13F filing for Q1 2021, filed 14 May 2021.